Valeant Pharmaceuticals' New Offer for Allergan Falls Short

Valeant Pharmaceuticals improves its offer for Botox maker Allergan, but long-term investors should want more

May 28, 2014 at 10:31PM
Longview

U.S. stocks were unable to add to yesterday's record high on Wednesday, but even as the benchmark S&P 500 broke a four-day winning streak, it fell just 0.1%. Meanwhile, the narrower Dow Jones Industrial Average (DJINDICES:^DJI) and the technology-heavy Nasdaq Composite Index (NASDAQINDEX:^IXIC) both fell 0.3%. In company-specific news, shares of Botox maker Allergan (NYSE:AGN) fell 5.4% today, even as its pursuer, Valeant Pharmaceuticals (NYSE:VRX), announced an improved offer, including a $10 increase in the cash component.

Images

Pfizer may have abandoned its ambitions with regard to AstraZeneca on Memorial day, but Valeant Pharmaceuticals shifted into higher gear in its pursuit of Allergan on Wednesday, with an improved cash-and-share offer worth $163.67, before one includes an exotic contingent value certificate based on the future success of Allergan's DARPin eye drug.

The following table sums up the proceedings to date:

Undisturbed Allergan closing share price on April 10, the day before activist investor Bill Ackman crossed the 5% ownership threshold

$116.63

Average Allergan closing share price over the 30-day period through April 10

$125.59

Initial Valeant offer, April 22

$149.11* per share

[0.83 Valeant share + $48.30 in cash]

Improved Valeant offer, May 28

$163.67 per share*

[0.83 Valeant share + $58.30 in cash componen]

+ Contingent Value Right in DARPin of up to $25 per share

Today's closing price

$156.12

Highest closing price since April 10

$169.91

*Based on Valeant's closing share price on May. 21
** Based on Valeant's closing share price on May. 28
Source: Author's calculations based on data from Yahoo! Finance and Valeant Pharmaceuticals

A higher offer was to be expected: Since Valeant announced its first offer on April 22, Allergan's stock has consistently traded at a premium to that offer. Indeed, based on Valeant's ultra-low effective tax rate and the $2.7 billion in cost savings it proposed to extract from the acquisition, Reuters BreakingViews calculated that the premium Valeant was offering Allergan shareholders initially was less than half of BreakingViews' $25 billion estimate of the value of the cost savings alone. As of today's close, Allergan's stock is trading at a 5% discount to Valeant's new offer, even excluding the contingent value rights, which is very tricky to value; indeed, the final details of the rights remain to be negotiated.

Valeant's offer to shareholders represents, at minimum, a 30% premium above the average price during the 30-day period through April 10, the day prior to activist crossing the 5% ownership threshold in Allergan shares. (Mr. Ackman teamed up with Valeant on its offer.)

Not a bad premium on the face of it, but I believe that long-term investors in Allergan ought to require a very healthy premium before they give up their shares. Allergan filed a presentation with the SEC today based on the research of two financial consulting and forensic accounting firms. The report suggests that Valeant Pharmaceutical's "roll-up" strategy, premised on frequent acquisitions, followed by R&D budget cuts (not to mention aggressive tax planning), is unsustainable. I'm inclined to agree with that assessment and, as such, I don't find the new offer compelling enough.

Here's your opportunity to make money in health care by investing in the next wave of innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion dollar industry." And the technology behind it is poised to set off one of the most remarkable health-care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.

Alex Dumortier, CFA has no position in any stocks mentioned. The Motley Fool recommends Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers